Sustained-hepatic arterial infusion of oxaliplatin: pharmacokinetic advantages over hepatic arterial infusion using a preclinical animal tumour model.
Drug delivery system
Emulsion
Ethiodised oil
Hepatic arterial infusion
Lipiodol
Liver tumours
Nanoparticle
Oxaliplatin
Pickering
Platform
Journal
Drug delivery and translational research
ISSN: 2190-3948
Titre abrégé: Drug Deliv Transl Res
Pays: United States
ID NLM: 101540061
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
accepted:
01
12
2020
pubmed:
13
1
2021
medline:
8
4
2022
entrez:
12
1
2021
Statut:
ppublish
Résumé
Hepatic arterial infusion (HAI) of oxaliplatin allows greater liver tumour drug exposure compared to systemic infusion. However, the therapeutic index of HAI oxaliplatin remains poor. Using Pickering emulsion technology, we developed a platform able to provide sustained releases of oxaliplatin. The goal of this study was to evaluate the pharmacokinetic advantages of sustained-HAI oxaliplatin over HAI using a preclinical animal tumour model. Injections of 0.6 mg oxaliplatin in 20 min were selectively done in left hepatic arteries of 20 rabbits bearing a VX2 liver tumour in the middle left-lobe, using HAI (n = 10) or sustained-HAI (n = 10). In each group, half of the rabbits were sacrificed at 24 h and half at 72 h. Mass spectrometry was used to quantify drug pharmacokinetics in blood and oxaliplatin concentrations in tumour tissues, right- and middle left-liver lobes, spleen and lung. Compared to HAI, sustained-HAI of oxaliplatin resulted in lower plasmatic peak (Cmax: 275 ± 41 vs. 416 ± 133 ng/mL, p = 0.02) and higher concentration in the tumour at 24 h (2118 ± 2107 vs. 210 ± 93 ng/g, p = 0.008). After HAI, oxaliplatin concentration in tumours was significantly higher than in lung at 24 h (p = 0.03) but no other difference was found between oxaliplatin concentrations in tumours and in liver lobes, spleen or lung, neither at 24 h nor at 72 h. On the opposite, sustained-HAI resulted in higher concentrations of oxaliplatin in tumour compared to oxaliplatin concentrations in the middle left lobe (163 ± 86 ng/g at 24 h, p = 0.01, and 90 ± 15 ng/g at 72 h, p = 0.04), right lobe (174 ± 112 ng/g at 24 h, p = 0.01, and 112 ± 35 ng/g, p = 0.04 at 72 h), spleen (142 ± 21 ng/g at 24 h, p = 0.01, and 98 ± 12 ng/g at 72 h, p = 0.04), and lung (85 ± 11 ng/g at 24 h, p = 0.01, and 52 ± 4 ng/g at 72 h, p = 0.03). Sustained-HAI improves the therapeutic index of HAI oxaliplatin and offers a great potential for patients suffering from unresectable colorectal liver metastases or hepatocellular carcinoma.
Identifiants
pubmed: 33432522
doi: 10.1007/s13346-020-00881-7
pii: 10.1007/s13346-020-00881-7
doi:
Substances chimiques
Oxaliplatin
04ZR38536J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2144-2150Informations de copyright
© 2021. Controlled Release Society.
Références
Doussot A, Kemeny NE, D’Angelica MI. Hepatic arterial infusional chemotherapy in the management of colorectal cancer liver metastases. Hepatol Oncol. 2015;2:275–90.
doi: 10.2217/hep.15.9
Chapelle N, Matysiak-Budnik T, Douane F, Metairie S, Rougier P, Touchefeu Y. Hepatic arterial infusion in the management of colorectal cancer liver metastasis: current and future perspectives. Dig Liver Dis. 2018;50:220–5.
doi: 10.1016/j.dld.2017.12.004
Karanicolas PJ, Metrakos P, Chan K, Asmis T, Chen E, Kingham TP, Kemeny N, Porter G, Fields RC, Pingpank J, et al. Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement. Curr Oncol. 2014;21:e129.
doi: 10.3747/co.21.1577
Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol. 1983;10:176–82.
pubmed: 6346495
Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31:3501–8.
doi: 10.1200/JCO.2012.44.5643
Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M. Gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005 Aug 1;23(22):4881–7.
Kern W, Beckert B, Lang N, Stemmler J, Beykirch M, Stein J, Goecke E, Waggershauser T, Braess J, Schalhorn A, et al. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol. 2001;12:599–603.
doi: 10.1023/A:1011186708754
Dzodic R, Gomez-Abuin G, Rougier P, Bonnay M, Ardouin P, Gouyette A, Rixe O, Ducreux M, Munck J-N. Pharmacokinetic advantage of hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anticancer Drugs. 2004;15:647–50.
doi: 10.1097/01.cad.0000131684.06390.fe
Guthoff I, Lotspeich E, Fester C, Wallin I, Schatz M, Ehrsson H, Kornmann M. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res. 2003;23:5203–8.
pubmed: 14981990
Ranieri G, Laforgia M, Nardulli P, Ferraiuolo S, Molinari P, Marech I, Gadaleta CD. Oxaliplatin-based intra-arterial chemotherapy in colo-rectal cancer liver metastases: a review from pharmacology to clinical application. Cancers (Basel). 2019 Jan 24;11(2).
Deschamps F, Isoardo T, Denis S, Tsapis N, Tselikas L, Nicolas V, Paci A, Fattal E, de Baere T, Huang N, Moine L. Biodegradable Pickering emulsions of Lipiodol for liver trans-arterial chemo-embolization. Acta Biomater. 2019;15(87):177–86.
doi: 10.1016/j.actbio.2019.01.054
Deschamps F, Harris KR, Moine L, Li W, Tselikas L, Isoardo T, Lewandowski RJ, Paci A, Huang N, de Baere T, Salem R, Larson AC. Pickering-emulsion for liver trans-arterial chemo-embolization with oxaliplatin. Cardiovasc Intervent Radiol. 2018;41(5):781–8.
doi: 10.1007/s00270-018-1899-y
Ramsden W. Separation of solids in the surface-layers of solutions and “suspensions” (observations on surface-membranes, bubbles, emulsions, and mechanical coagulation). -- Preliminary Account, Proc. R. Soc. London. 72 (1903) 156–164. https://doi.org/10.1098/rspl.1903.0034 .
Pickering SU. CXCVI.—Emulsions, J. Chem. Soc., Trans. 91 (1907) 2001–2021. https://doi.org/10.1039/CT9079102001 .
Guzman LA, Labhasetwar V, Song C, Jang Y, Lincoff AM, Levy R, Topol EJ. Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty., Circulation. 94 (1996) 1441–8. http://www.ncbi.nlm.nih.gov/pubmed/8823004 (accessed August 22, 2018).
Grabowski N, Hillaireau H, Vergnaud J, Tsapis N, Pallardy M, Kerdine-Römer S, Fattal E. Surface coating mediates the toxicity of polymeric nanoparticles towards human-like macrophages. Int J Pharm. 2015;482:75–83. https://doi.org/10.1016/j.ijpharm.2014.11.042 .
doi: 10.1016/j.ijpharm.2014.11.042
pubmed: 25448553
Grabowski N, Hillaireau H, Vergnaud-Gauduchon J, Nicolas V, Tsapis N, Kerdine-Römer S, Fattal E. Surface-modified biodegradable nanoparticles’ impact on cytotoxicity and inflammation response on a co-culture of lung epithelial cells and human-like macrophages. J Biomed Nanotechnol. 2016;12:135–46.
doi: 10.1166/jbn.2016.2126
Deschamps F, Moine L, Isoardo T, Tselikas L, Paci A, Mir LM, Huang N, Fattal E, de Baère T. Parameters for stable water-in-oil lipiodol emulsion for liver trans-arterial chemo-embolization. Cardiovasc Intervent Radiol. 2017;40(12):1927–32.
doi: 10.1007/s00270-017-1763-5
Malka D, Paris E, Caramella C, Boucher E, Guimbaud R, Celebic A, De Baere T, Elias D, Pignon J, Ducreux M. Hepatic arterial infusion (HAI) of oxaliplatin plus intravenous (iv) fluorouracil (F U), leucovorin (LV), and cetuximab for first-line treatment of unresectable colorectal liver metastases (CRLM) (CHOICE): A multicenter phase II study. J Clin Oncol 28:15s, 2010 (suppl; abstr 3558).
Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, Dromain C, Pocard M, Ducreux M. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol. 2008;15(1):219–26.
doi: 10.1245/s10434-007-9581-7
Goere D, Deshaies I, de Baere T, Boige V, Malka D, Dumont F, Dromain C, Ducreux M, Elias D. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010;251(4):686–91.
doi: 10.1097/SLA.0b013e3181d35983
Lyu N, Lin Y, Kong Y, Zhang Z, Liu L, Zheng L, et al. FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma. Gut Published Online First: 07 June 2017. https://doi.org/10.1136/gutjnl-2017-314138 .
Rathore R, Safran H, Soares G, Dubel G, McNulty B, Ahn S, et al. Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study. Am J Clin Oncol. 2010;33:43–6.
doi: 10.1097/COC.0b013e31819d8668
Lyu N, Kong Y, Pan T, Mu L, Li S, Liu Y, Deng H, Li J, Shi M, Xu L, Guo R, Chen M, Wu P, Zhao M. Hepatic Arterial infusion of oxaliplatin, fluorouracil, and leucovorin in hepatocellular cancer with extrahepatic spread. J Vasc Interv Radiol. 2019;30(3):349-357.e2. https://doi.org/10.1016/j.jvir.2018.09.004 .
doi: 10.1016/j.jvir.2018.09.004
pubmed: 30819477
Lyu N, Kong Y, Luwen Mu, Lin Y, Li J, Liu Y, Zhang Z, Zheng L, Deng H, Li S, Xie Q, Guo R, Shi M, Li Xu, Cai X, Peihong Wu, Zhao M. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin versus sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2018;69(1):60–9. https://doi.org/10.1016/j.jhep.2018.02.008 .
doi: 10.1016/j.jhep.2018.02.008
pubmed: 29471013